sclc2388_S39.txt
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_6NTXGQAC | Ganglioglioma | — | 0.911 |
| 2 | ERR2598319 | fetal | fetal | 0.903 |
| 3 | MDT-AP-0410 | Med | Medulloblastoma | 0.900 |
| 4 | MDT-AP-1254 | Med | Medulloblastoma | 0.892 |
| 5 | ERR2598312 | fetal | fetal | 0.890 |
| 6 | SAMN03290935 | — | — | 0.889 |
| 7 | SRR2774182 | — | — | 0.885 |
| 8 | MDT-AP-0484 | Med | Medulloblastoma | 0.885 |
| 9 | SJEPD037_R.RNA-Seq | EPN | Posterior Fossa EPN | 0.885 |
| 10 | SRR1431345 | GTEX | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |